Nov 06, 2019
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
Nov 04, 2019
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs
Oct 21, 2019
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019
Sep 17, 2019
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
Aug 01, 2019
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
Jul 08, 2019
The global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period
Jun 18, 2019
DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
May 07, 2019
DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs
Mar 27, 2019
DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
Nov 19, 2018
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
Aug 01, 2018
DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Apr 25, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
Mar 29, 2018
DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis